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ABSTRACT
Background Both pathogenic bacteria and viruses are 
frequently detected in the nasopharynx (NP) of children in the 
absence of acute respiratory infection (ARI) symptoms. The 
aim of this study was to estimate the aetiological fractions 
for ARI hospitalisation in children for respiratory syncytial 
virus (RSV) and influenza virus and to determine whether 
detection of specific respiratory pathogens on NP samples 
was associated with ARI hospitalisation.
Methods 349 children up to 5 years of age hospitalised for 
ARI (following a symptom- based case definition) and 306 
hospital controls were prospectively enrolled in 16 centres 
across seven European Union countries between 2016 and 
2019. Admission day NP swabs were analysed by multiplex 
PCR for 25 targets.
Results RSV was the leading single cause of ARI 
hospitalisations, with an overall population attributable 
fraction (PAF) of 33.4% and high seasonality as well as 
preponderance in younger children. Detection of RSV on 
NP swabs was strongly associated with ARI hospitalisation 
(OR adjusted for age and season: 20.6, 95% CI: 9.4 to 45.3). 
Detection of three other viral pathogens showed strong 
associations with ARI hospitalisation: influenza viruses had 
an adjusted OR of 6.1 (95% CI: 2.5 to 14.9), parainfluenza 
viruses (PIVs) an adjusted OR of 4.6 (95% CI: 1.8 to 11.3) 
and metapneumoviruses an adjusted OR of 4.5 (95% CI: 
1.3 to 16.1). Influenza viruses had a PAF of 7.9%, PIVs of 
6.5% and metapneumoviruses of 3.0%. In contrast, most 
other pathogens were found in similar proportions in cases 
and controls, including Streptococcus pneumoniae, which 
was weakly associated with case status, and endemic 
coronaviruses.
Conclusion RSV is the predominant cause of ARI 
hospitalisations in young children in Europe and its 
detection, as well as detection of influenza virus, PIV or 
metapneumovirus, on NP swabs can establish aetiology with 
high probability. PAFs for RSV and influenza virus are highly 
seasonal and age dependent.
INTRODUCTION
The Global Burden of Disease Study 2015 
estimates that acute respiratory infections 
(ARIs) cause more than 15% of under- five 
mortality.1 Approximately 102 million cases of 
Key messages
 ► The study investigated which pathogens cause hos-
pitalisation with acute respiratory infection (ARI) in 
preschool children in Europe
 ► Causes of children’s ARIs needing hospitalisation 
in Europe do not differ from other world regions. In 
upper airway samples, most pathogens, but not re-
spiratory syncytial virus and influenza, are found at 
similar frequency in healthy and ill children.
 ► ARIs are the most common reason for hospitalisation 
in children and are most commonly caused by virus-
es, not bacteria in this setting where pneumococcal 
conjugate vaccine use is common and influenza 
vaccine use is not common among young children.
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pneumonia resulting in 0.7 million deaths occurred each 
year in children under 5 years of age.2 While compared 
with low- resource settings case fatality in paediatric ARI 
in Europe is much lower,3 ARI remains the most frequent 
reason for hospitalisation in children.4 In children under 
the age of 5, respiratory viruses are detected in up to 80% 
of ARI cases.5 6 While Streptococcus pneumoniae remains 
the most prevalent bacterial pathogen,7 8 the propor-
tion of bacterial ARI and prevalence of bacterial coloni-
sation have declined with widespread use of conjugate 
vaccines.4 9–11 However, the frequency of treatment of 
ARI with antibiotics has not declined accordingly.12
Both in paediatric clinical care and research, nasopha-
ryngeal (NP) samples are the only microbiological spec-
imen that can routinely be obtained.13 Children’s upper 
airways are regularly colonised by potentially pathogenic 
bacteria or they are asymptomatic carriers of respiratory 
viruses.14 In a study on community- acquired pneumonia 
(CAP) among children in the USA, bacterial patho-
gens were identified in a minority of cases, with viruses, 
particularly respiratory syncytial virus (RSV) in younger 
and human rhinovirus (HRV) in older children, being 
identified in the majority.15 Codetection of viruses and 
bacteria is common.5 7 16 Codetection has been associated 
with more severe disease in some,17 18 yet not in other 
studies.19 20 Viral–bacterial codetection has mostly been 
shown to be associated with more severe disease, while 
codetection of several viruses was more often unrelated 
to severity.21 For S. pneumoniae, prevalence of upper 
airway colonisation peaks at around 3 years of age.22
Recent studies in Africa, Asia and North America, 
conducted in an era of widespread routine vaccina-
tion against encapsulated bacteria, show that the bulk 
of disease is caused by viral infections (predominantly 
RSV and HRV).15 23 The Pneumonia Etiology Research 
for Child Health study compared more than 4000 chil-
dren admitted for CAP with more than 5000 commu-
nity controls in seven countries in sub- Saharan Africa 
and South- East Asia and in contrast to earlier findings, 
showed that RSV had by far the highest aetiological 
fraction (31%) of all studied pathogens.23 Surprisingly, 
comparable data are not available for Europe. Both RSV 
and influenza viruses show distinct seasonal patterns in 
Europe.24 According to the European Centre for Disease 
Prevention and Control, pneumococcal conjugate 
vaccines (PCVs) have been introduced into routine infant 
vaccination schedules in the majority of European coun-
tries. However, influenza vaccines are only part of vaccina-
tion plans for children with increased risk, for example, 
due to comorbidities. Pronounced seasonality of ARI in 
Europe and potentially differing and changing epidemi-
ology warranted a multicentre European study including 
cases hospitalised with ARI and healthy controls.
PREPARE (Platform for European Preparedness 
Against (Re- )emerging Epidemics) is a European 
Commission- funded network for harmonised large- scale 
clinical research studies on infectious diseases, prepared 
to rapidly respond to any severe infectious disease 
outbreak. The Multi- centre EuRopean study of MAjor 
Infectious Disease Syndromes (MERMAIDS) is the part 
of the PREPARE platform including case–control and 
cohort studies on aetiology and management of ARI.
The aim of this study was to estimate the aetiological 
fractions for ARI hospitalisation in children for RSV and 
influenza virus, both pathogens with a strongly seasonal 
occurrence in Europe, and to determine whether detec-
tion of specific respiratory pathogens in upper airway 
samples was associated with ARI hospitalisation. In line 
with the general mission of PREPARE, a secondary 
study aim was to build a European network of paediatric 




The study was a case–control study with collection of 
clinical data and samples at baseline and follow- up of 
cases until discharge. Primary objective was to estimate 
the proportion of cases attributable to specific respira-
tory pathogens. Cases and controls were enrolled 
continuously throughout the year between September 
2016 and March 2019 at 16 secondary or tertiary hospi-
tals in seven European countries (Belgium, Germany, 
Greece, Italy, Lithuania, Spain and theUK). PCV was 
part of routine vaccination schedules within the first 
6 months of life in all of these countries and influenza 
vaccines were not recommended as routine vaccines 
in any. Participants were recruited as they presented 
to paediatric departments, where they were screened 
for eligibility, mainly during daytime hours with high 
level of staffing. Total numbers of presenting eligible 
patients and number of screened patients were not 
systematically collected. Parents of all participants gave 
written informed consent and the study was approved by 
the responsible ethics committees at all sites. The study 
was designed to be as minimally invasive as possible 
and only pathogen detection samples were taken from 
all children. This protocol was written without patient 
involvement. Patients or guardians were not invited to 
comment on the study design or to contribute to the 
writing or editing of this document for readability or 
accuracy.
The protocol is available on the PREPARE website: 
https:// prepare. ersnet. org/ trials- protocols. aspx.
Case and control groups
Participants were otherwise healthy children under 6 
years of age. Patients with temperature ≥38°C hospital-
ised due to a new episode of ARI according to a clinical 
definition were included in the study as cases. Controls 
were afebrile children attending the same hospitals for 
scheduled procedures or visits not related to infections 
and who did not fulfil clinical criteria for the case group 
but may have had mild symptoms of ARI. Hospital 
controls rather than community controls were chosen 
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for feasibility. To be included for the case–control study, 
an NP sample (as specified in the section on pathogen 
detection) had to be obtained. Eligibility criteria are 
listed in table 1. Matching of controls to cases by age, 
season and site of recruitment was attempted but not 
consistently successful.
Pathogen detection
NP swabs for pathogen detection were collected for cases 
and controls at admission (within 24 hours), or for some 
controls during an outpatient clinic visit. Samples were 
frozen at −80°C until shipment to the central study labo-
ratory at the University of Antwerp, where specimens were 
stored at −80°C until analysis. NP samples were extracted 
with the NucliSens EasyMag (bioMérieux, France) by 
using the specific A protocol. The FTD Respiratory Path-
ogens 21 plus (Fast Track Diagnostics, Ltd, Luxembourg) 
was applied according to the instructions of the manufac-
turer for the qualitative detection of influenza A, influ-
enza B, influenza A- H1N1, human coronaviruses NL63, 
229E, OC43 and HKU1, parainfluenza viruses (PIVs) 1, 
2, 3 and 4, human metapneumovirus A and B, HRV, RSV 
A and B, adenovirus, enterovirus, parechovirus, boca-
virus, Mycoplasma pneumoniae, Chlamydophila pneumoniae, 
S. pneumoniae, Haemophilus influenzae b and Staphylococcus 
aureus.
Table 1 Complete inclusion and exclusion criteria
Case group Control group
Inclusion criteria
Age <6 years old on the day of admission
Clinical suspicion of a new episode of ARI within the last 
7 days
One of the following
1. Attending for an elective or semielective procedure 
requiring general anaesthesia or moderate- deep sedation 
(including, eg, surgery, radiological examinations etc).
2. Well and otherwise healthy children attending an outpatient 
clinic for a non- emergency clinical assessment.
The attending physician has decided that the child requires 
hospitalisation
Primary reason for hospital admission was clinical suspicion of 
a new episode of ARI
Temperature ≥38°C measured by any method (reported within 
24 hours or at presentation)
Afebrile on the day of enrolment
And at least two of the below (with at least one of 1 or 2):
1. Signs of lower respiratory tract infection: cough, abnormal 
sounds on chest auscultation (crackles, reduced breath 
sounds, bronchial breathing, wheezing), dyspnoea (chest 
indrawing, nasal flaring, grunting).
2. Signs of upper respiratory tract infection: coryza, nasal 
congestion, sore throat, pharyngitis, myringitis, acute otitis 
media.
3. Signs of respiratory dysfunction: tachypnoea for age or 
brady/apnoea or decreased oxygen saturation (<92% in 
room air).
4. Signs of reduced general state: poor feeding, vomiting, 
lethargy/drowsiness.
No evidence of severe infection as judged by attending 
physician
Exclusion criteria
Inpatient care for 24 hours or more for any condition within the previous 30 days, except for routine postnatal care
Immunocompromised infant (stem cell transplant, solid organ transplant, HIV, AIDS, immunosuppressive therapy, primary 
immunodeficiency, haemodialysis)
Presence of complex chronic comorbidities39
Body weight <3 kg on day of assessment and/or corrected gestational age <37 weeks
Aetiology other than infection (such as trauma, autoimmune 
disorder, malignancy) is suspected to be the primary cause of 
the current illness episode
Temperature ≥38°C or <36°C
Any signs and symptoms suggesting a clear primary focus 
of infection, such as urinary tract infection, open wounds, 
indwelling catheters, reactivation of previously diagnosed 
infectious or inflammatory condition
Dehydration due to previous illness episode such as diarrhoea 
and vomiting
ARI, acute respiratory infection.
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Data management and statistics
Demographic data, focused medical history, clinical 
characteristics on admission, focused aspects of patient 
management and final outcome were entered into elec-
tronic case report forms hosted by the Julius Center at the 
University of Utrecht. Data were checked for complete-
ness at the end of the study and data queries completed 
within 6 months of inclusion of the last participant.
The sample size was determined before the study 
started based on estimates for the proportions of chil-
dren who were positive for RSV and influenza virus. With 
an expected positive proportion for influenza of 10% in 
cases and 3% in controls and aiming for 90% power and 
alpha=5% for an OR larger than 1.0, the required sample 
size for influenza was 320 per group. The required sample 
size for RSV was 40 per group (expected 25% positive 
in cases and 1% in controls). As these sample sizes were 
not additional, the total required sample size followed 
the calculation for influenza and was therefore 640 (320 
cases and 320 controls).
Data handling and statistical operations were 
performed in Stata V.14. Complete records analysis was 
done throughout, as missing data were rare (below 5% 
on individual variables, none on pathogen detection and 
no dropped observations on covariate analyses). For cate-
gorical variables, p values were obtained by χ2 test and for 
continuous variables by Wilcoxon rank- sum test due to 
the non- normal distribution of their values. Necessitated 
by incomplete matching, adjusted ORs were calculated 
by logistic regression with age and season of recruitment 
as covariates, p values were obtained by Wald test. For 
adjusted ORs, sensitivity analyses were performed to 
explore if these differed based on (1) coadjusting for 
country of inclusion, because proportions of cases and 
controls among the participants differed by country and 
(2) using a control group restricted to completely asymp-
tomatic children. The population attributable fraction 
(PAF) was calculated by substituting the OR for the risk 
ratio where detection of the pathogen in the control 
group was sufficiently rare to allow for this substitution.25
RESULTS
A total of 349 cases and 306 controls were enrolled from 
16 sites in seven countries during the study period, with 
approximately three- quarters of cases and two- thirds 
of controls enrolled in the main European ARI season 
between October and March. Sixty- one per cent of 
participants were male, with cases slightly younger than 
controls. The proportions of cases and controls included 
in the participating countries differed (table 2).
Clinical course
In cases, the median time to presentation in the emer-
gency department, from first day of onset of symptoms 
was 2 days (IQR: 1–4). The most common symptom on 
presentation was poor feeding, seen in 241 (69.3%), 190 
(54.4%) had chest recessions, 137 (39.4%) wheezing and 
109 (31.2%) had a fever of >39°C. A relevant propor-
tion of cases had signs of more severe disease: 26 (7.5%) 
required supplemental oxygen on admission and 12 
(3.5%) had a central capillary refill time of >2 s. Of the 
controls, 33 (10.8%) had mild illness as reported by 
parents during the previous 7 days but did not fulfil inclu-
sion criteria as a case.
The majority of cases had disease clinically classified 
as lower respiratory tract infection (LRTI). About 59.3% 
of cases were treated with antibiotics during their admis-
sion. Among cases diagnosed as LRTI, 68.6% received 
antibiotics, compared with 34.8% among children with 
upper respiratory tract infection (URTI) and 35.7% with 
unspecified infection.
Detected potential pathogens in cases and controls
Figure 1A shows prevalence of detection of respiratory 
pathogens in study samples. S. pneumoniae was the most 
prevalent target detected in cases and controls. The 
second most frequent potentially pathogenic bacteria 
found was S. aureus, which was the only one weakly associ-
ated with being a control rather than a case (OR for case 
status: 0.7, 95% CI: 0.5 to 1).
Respiratory viruses were detected in >80% of cases 
and >40% of controls. The respiratory virus most 
frequently detected was HRV, which was found in >20% 
of both cases and controls. Eighty per cent (32 of 40) of 
the detected influenza viruses were influenza A, among 
these 22 (68.8%) were influenza A- H1N1. All influenza 
B were isolated from children in the case group, but 
due to the small number of isolates this may likely be 
random.
Human coronaviruses were detected at similar 
frequencies, between 5% and 10%, in both cases and 
controls and showed no predominance for any age 
(median age in years among coronavirus negative: 
1.39, IQR: 0.49 to 3.20; among coronavirus positive: 
1.34, IQR: 0.59 to 2.40; p=0.642). All four endemic 
coronaviruses were evenly distributed between cases 
and controls (229E in 7 cases and 5 controls, NL63 in 
3 cases and 5 controls, HKU1 in 4 cases and 7 controls 
and OC43 in 8 cases and 10 controls).
Codetection of potentially pathogenic bacteria and 
viruses was common in both groups (51.9% in cases 
and 28.8% in controls). Among the 187 cases in which 
both bacteria and viruses were found, RSV was found 
in 74 and influenza virus in 16. S. pneumoniae was the 
bacterial potential pathogen found in most codetection 
cases (83.4%) and S. aureus was detected in 32.1%. In 
contrast, among controls with detection of both viruses 
and bacteria simultaneously, only very few carried RSV 
or influenza virus (7 and 3, respectively) but 43 (48.9%) 
carried rhinovirus and proportions positive for S. pneu-
moniae (87.5%) and S. aureus (38.6%) were similar as 
in cases.
Other respiratory pathogens were detected in only very 
low proportions of participants: M. pneumoniae in three 
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cases (0.9%) and no controls, C. pneumoniae was not 
detected in any cases but in three controls (1.0%) and H. 
influenzae b was not detected in either group.
No potential respiratory pathogen was detected in 
only 27.1% of controls and 4.3% of cases. Figure 1B illus-
trates clear evidence of a higher frequency of detection 
of RSV (OR: 23.0, 95% CI: 10.5 to 59.2), influenza virus 
(OR: 5.4, 95% CI: 2.2 to 15.9), PIV (OR: 4.5, 95% CI: 
1.8 to 13.5) and metapneumovirus (OR: 4.2, 95% CI: 
1.2 to 23.1) in cases compared with controls.
Proportions of patients with detection of no pathogen, 
only bacteria, only viruses or both viruses and bacteria 
did not change depending on prior duration of symp-
toms in days (p=0.502).
There was no difference in the frequency of antibi-
otic prescriptions when comparing different groups of 
detected pathogens. Antibiotics were given in 62.5% of 
children with no pathogen detected, 65.7% with only 
bacteria detected, 63.6% with only viruses detected and 
52.9% with viruses and bacteria detected (p=0.158). 
There was no difference in prevalence of antibiotics in 
children who tested positive for RSV (61.3% received 
antibiotics, compared with 56.5% in RSV negative, 
p=0.637) or positive for influenza virus (56.9% received 
antibiotics, compared with 55.8% in influenza negative, 
p=0.479).
Age and season dependency of pathogen detection
Table 3 presents the breakdown of detection of RSV, 
influenza, parainfluenza, metapneumovirus and S. pneu-
moniae. As expected, RSV was more commonly found in 
younger children and almost 90% of detection of influ-
enza virus occurred between January and March. PIV 
was more often detected in children of the two younger 
age groups and in autumn or summer as compared with 
Table 2 Demographics, season of inclusion, treatment and outcome
Groups ARI Control P value
Total inclusions (N) 349 306 –
Sex (male, n, %) 202 (57.9) 200 (65.4) <0.001
Age in years (median, IQR) 1.09 (0.42 to 2.49) 1.80 (0.93 to 3.65) <0.001
Age range (n, %)
  <12 months 160 (45.9) 83 (27.1) <0.001
  12–<36 months 120 (34.4) 114 (37.3)
  ≥36 months 69 (19.8) 109 (35.6)
Inclusion by season (n, %)
  October–December 76 (21.8) 85 (27.8) <0.001
  January–March 182 (52.2) 115 (37.6)
  April–September 91 (26.1) 106 (34.6)
Inclusion by country (n, %)
  Greece 144 (41.3) 50 (16.3) <0.001
  Italy 85 (24.4) 46 (15.0)
  Spain 45 (12.9) 45 (14.7)
  UK 55 (15.8) 94 (30.7)
  Other 20 (5.7) 71 (23.2)
Symptom onset prior to inclusion in days (median, IQR) 2 (1 to 4) – –
IVF during inpatient stay (n, %) 184 (52.7) – –
Antibiotic treatment (n, %) 207 (59.3) – –
PICU admission 9 (2.6) – –
Length of hospital stay in days (median, IQR) 3 (2 to 5) – –
Clinician diagnosis at discharge
  URTI 69 (19.8) – –
  LRTI 245 (70.2) –
  Unspecified 35 (10.0) –
Died (n, %) 0 (0.0) – –
P values were obtained using χ2 test or Wilcoxon rank- sum test as applicable.
ARI, acute respiratory infection; IQR, interquartile range 
; IVF, intravenous fluid; LRTI, lower respiratory tract infection; PICU, paediatric intensive care unit; URTI, upper respiratory tract infection.
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winter. Detection of metapneumovirus was evenly distrib-
uted among age groups and seasons.
Additionally, online supplemental table 1 provides 
numbers and proportions of participants with detection 
of all pathogens presented in figure 1 by case or control 
status. Parechovirus was more often detected in cases 
in autumn (6.6%, compared with 1.1% in winter and 
0% in summer, p=0.011) and enterovirus more often 
in summer (8.8%, compared with 1.3% in autumn and 
1.7% in winter, p=0.011). Other pathogens showed no 
distinct seasonality.
Because both age and season of recruitment were 
distributed differently between cases and controls, we 
calculated OR estimates adjusted for these covariates. 
As shown in table 4, the adjusted ORs did not differ 
markedly from the crude ORs presented in figure 1B. 
Detection of RSV was very strongly associated with being 
a case (OR: 20.6). To a lesser degree, this is also true 
for influenza virus (OR: 6.1), PIV (OR: 4.6) and metap-
neumovirus (OR: 4.5). For S. pneumoniae, the associa-
tion of detection and case status was weaker (OR: 1.7). 
The sensitivity analysis including country of inclusion 
Figure 1 Prevalence of respiratory pathogens or combinations (A) and respective ORs for detection (B). (A) Prevalence of 
respiratory pathogens in nasopharyngeal swabs at hospital admission in percent, dark grey bars for cases, light grey bars for 
controls. (B) ORs with 95% CIs for detection in cases compared with controls. RSV, respiratory syncytial virus.


















































































RSV, respiratory syncytial virus.
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as a covariate indicated that, after multivariate adjust-
ment, country of inclusion had no effect on the asso-
ciation between pathogens and case status (table 5). 
When restricting the analysis to controls without any 
symptoms of respiratory infection, ORs for S. pneumo-
niae and influenza virus remained similar, but the asso-
ciation between detection of RSV or metapneumovirus 
and case status became even more pronounced (RSV—
OR: 42.6, metapneumovirus—OR: 6.2).
Age-specific and season-specific PAF estimates
As S. pneumoniae (and some respiratory viruses including 
HRV) were commonly detected in controls, PAF was not 
estimated. For RSV, the overall PAF was 33.4% and for 
influenza virus 7.9%. Due to the specific distribution char-
acteristics of these viruses there were, however, marked 
differences between the PAF estimates for different age 
groups and at different times of the year (table 6). For 
PIV, the overall PAF was 6.5% and for metapneumovirus 
3.0%. Estimation of age- group and season- specific PAF 
was unfeasible due to low overall detection numbers.
Between the months of October and March, RSV caused 
close to 50% of ARI hospitalisation in children under the 
age of 1 and a third of ARI hospitalisation in children 
aged 2–3 years in this study. These fractions did not differ 
between the autumn months (October–December) and 
winter months (January–March). In contrast, the PAF for 
influenza virus was highest in winter and in children over 




The aetiology of severe ARI requiring hospitalisation 
in children from this European case–control study 
is consistent with previously reported results from 
other settings.15 23 These findings show that RSV was 
the dominant respiratory pathogen in preschool chil-
dren during the study period, causing a third of ARI 
Table 4 OR of detection in cases compared with controls 
by multiplex PCR in nasopharyngeal swabs, by pathogen, 
adjusted for age and season (logistic regression)
Pathogen
Adjusted 
OR 95% CI P value
Streptococcus 
pneumoniae
1.7 1.2 to 2.3 0.002
RSV 20.6 9.4 to 45.3 <0.001
Influenza virus 6.1 2.5 to 14.9 <0.001
Parainfluenza virus 4.6 1.8 to 11.3 0.001
Metapneumovirus 4.5 1.3 to 16.1 0.021
No pathogen 
detected
0.1 <0.1 to 0.2 <0.001
P values were obtained by Wald test.
RSV, respiratory syncytial virus.
Table 5 Sensitivity analyses for OR of detection in cases compared with controls, by pathogen, adjusted for age and season 
(logistic regression)
Pathogen
Additionally adjusted for country of inclusion Excluding mildly symptomatic controls
Adjusted OR 95% CI P value Adjusted OR 95% CI P value
Streptococcus 
pneumoniae
1.63 1.17 to 1.27 0.003 1.95 1.39 to 2.73 <0.001
RSV 20.7 9.38 to 45.82 <0.001 42.6 13.31 to 136.29 <0.001
Influenza virus 6.38 2.56 to 15.88 <0.001 6.38 2.42 to 16.81 <0.001
Parainfluenza virus 4.87 1.93 to 12.28 0.001 4.02 1.63 to 9.96 0.003
Metapneumovirus 4.04 1.10 to 14.79 0.035 6.20 1.37 to 28.02 0.018
No pathogen detected 0.12 0.07 to 0.22 <0.001 0.10 0.05 to 0.18 <0.001
P values were obtained by Wald test.
RSV, respiratory syncytial virus.










  October–December 48.0 38.1 20.0
  January–March 48.1 35.6 19.2
  April–September 23.5 16.7 4.8
Influenza virus
Season
  October–December -* 8.0 3.8
  January–March 11.0 9.5 30.3
  April–September 3.0 -* 4.8
No estimates for S. pneumoniae are presented due to its high 
prevalence in the control group (see Methods for details) and 
for PIV and metapneumovirus due to low overall detection 
numbers.
*None detected in cases or controls.
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hospitalisations. Detection of RSV in healthy children 
was rare. In our study, half of ARI hospitalisations could 
be attributed to the four pathogens with the strongest 
association with ARI hospitalisation, that is, RSV, influ-
enza virus, PIV and metapneumovirus.
Both RSV and influenza virus are highly seasonal, and 
their prevalence was associated with patient age. However, 
the strength of their association with being hospitalised 
for ARI did not differ between age groups and seasons. 
This suggests that their detection is highly predictive for 
aetiology of an ARI episode even in patients who are not 
part of the typical risk group (ie, infants for RSV) or who 
present outside the pathogen’s main season. Compared 
with data from studies set in sub- Saharan Africa and 
South- East Asia, influenza viruses were more commonly 
detected in children hospitalised for ARI in this study.7 23 
While the PAF is therefore higher in Europe, the associ-
ation of detected virus with clinical disease was similar 
across settings.23 PIV was more often detected in autumn 
and summer compared with the winter months when 
most patients with ARI are hospitalised. This suggests 
that it may have a high PAF in months with a lower 
frequency of cases. However, numbers of PIV detection 
were too low in this study to demonstrate this.
S. pneumoniae was the most frequently detected respi-
ratory pathogen in NP swabs from both children hospi-
talised for ARI and healthy controls but was not a strong 
predictor of hospitalisation for ARI. This is consistent 
with previous findings of an age- related dynamic with 
high nasopharyngeal colonisation rate by S. pneumoniae 
in infancy and early childhood.22 Therefore, detection 
of S. pneumoniae on upper airway samples is unable to 
reliably establish the aetiology of an ARI episode. S. 
aureus was more frequently found in control children. 
S. aureus may cause LRTIs and is especially common as a 
cause of superinfections following influenza. However, 
its detection in NP specimens was not indicative of ARI. 
An inverse relationship between carriage of S. pneumo-
niae and S. aureus may explain this finding due to S. 
pneumoniae being a more common cause of ARI. This 
has been suggested, but study results are contradic-
tory.26 27
The higher proportion of codetection of viruses and 
bacteria in cases as compared with controls was almost 
exclusively accounted for by higher proportions of chil-
dren infected with RSV or influenza virus. Thus, the 
association between codetection of viruses and bacteria 
with being hospitalised for ARI in our study likely 
reflects the importance of viruses in causing severe 
respiratory symptoms in young children rather than 
suggesting true co- infections.
The low rate of detection of less- common causes of 
pneumonia, such as M. pneumoniae and C. pneumoniae, 
is likely due to the generally low prevalence of these 
pathogens in the studied age group.28 The absence of H. 
influenzae b is not surprising, as carriage and infections 
have virtually disappeared since the introduction of the 
vaccine.29
This study ended before the beginning of the current 
COVID-19 pandemic. The four previously endemic 
coronaviruses were found in similar and low propor-
tions in both cases and controls and were not associ-
ated with case status. Therefore, although they may 
have caused ARI hospitalisation in some children, their 
detection on NP swabs was not sufficient to establish 
them as causative pathogens of ARI.
The study’s aim of capacity building proved to be crucial 
regarding the current pandemic. With the onset of the 
pandemic, the study network was instantly able to provide 
information on patient management strategies and to 
facilitate site participation in the WHO- initiated ISARIC 
Clinical Characterisation Protocol.30 31 Further, several 
study sites are participating in subsequently launched 
consortia funded by the European Commission.
A limitation of this study is that we only analysed 
upper airway samples. Previous multiplex PCR- based 
studies confirmed a high concordance between respi-
ratory pathogens found in upper and lower airways, 
but especially with regard to specific pathogens discor-
dance has been reported.32–34 By restricting the samples 
to NP samples, the study may still have missed a stronger 
association of lower airway carriage of bacteria with ARI 
hospitalisation. Nevertheless, restricting samples to NP 
swabs best reflects the situation in paediatric clinical 
care.
Another important limitation is that we did not 
systematically record numbers of screened patients 
and that both cases and controls were convenience 
samples. Because of differing thresholds for patient 
admission it is difficult to compare severity of disease in 
hospitalised children with ARI between high- resource 
and low- resource settings, but on average hospital-
ised children in high- resource settings have milder 
disease.35 Very few children in our sample required 
intensive care unit treatment on admission, and this is 
consistent with the low case fatality of childhood ARI 
in high- resource settings.3 Poor feeding was the most 
frequently observed clinical ARI sign. Poor feeding 
can be seen in the majority of children with RSV bron-
chiolitis and is often the cause for hospitalisation.36 
In terms of disease severity, the group of cases in our 
study does not seem to differ from children included 
in other studies on hospitalisations for ARI (including, 
but not exclusively, CAP) in comparable settings.37 
Although overall case severity showed a good repre-
sentation of the intended group, it is nonetheless 
possible that convenience sampling biased associa-
tions between detected pathogens and hospitalisation 
in either direction.
The study was conducted in a setting where in all 
places PCV was part of routine infant vaccine schedules 
and influenza vaccine was not. Therefore, the study 
cannot provide evidence on the effect of these vaccines 
on aetiology of childhood ARI hospitalisation and may 
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Hospital controls are less likely to have symptoms 
than children in the community, as those with symp-
toms may not attend hospital visits or may postpone 
elective procedures. Children were still included in the 
control group if they showed symptoms of mild disease 
as long as they did not meet case criteria as this has 
been shown to result in a control group most represen-
tative of the general population.14 Exclusion of controls 
with mild respiratory symptoms would lead to an over-
estimation of the association between pathogens and 
hospitalisation, especially for pathogens rarely found in 
asymptomatic children. Some overestimation of these 
associations may still have occurred due to the choice 
of hospital controls rather than community controls.
This study is the first to present findings on the aeti-
ology of hospitalisations for ARI applying the same 
protocol across sites in seven European countries. The 
results illustrate that the causes of severe ARI requiring 
hospital admission do not differ profoundly between 
these European and other global settings. However, 
the pronounced seasonality of circulation of RSV and 
influenza virus as major causal agents leads to differing 
probabilities of infection with these pathogens in an 
individual patient, strongly depending on age and time 
of year.
Previous studies have shown that reduction of inap-
propriate antibiotic prescriptions in emergency depart-
ments can be achieved with antibiotic stewardship 
programmes.38 Our study provides evidence that detec-
tion of RSV and influenza virus on NP samples can 
strongly support a suspected viral aetiology of ARI and 
may therefore help to reduce antibiotic prescriptions.
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Pathogen in cases (% positive) in controls (% positive) 
Oct – Dec Jan – Mar Apr – Sep Oct – Dec Jan – Mar Apr – Sep 
S. pneumoniae 45 (59.2) 84 (46.2) 50 (55.0) 34 (40.0) 47 (40.1) 46 (43.4) 
RSV 28 (36.8) 79 (43.4) 15 (16.5) 2 (2.4) 5 (4.4) 0 (0.0) 
rhinovirus 23 (30.3) 44 (24.2) 36 (39.6) 23 (27.1) 17 (14.8) 22 (20.8) 
S. aureus 19 (25.0) 32 (17.6) 20 (22.0) 22 (25.9) 30 (26.1) 31 (29.3) 
bocavirus 5 (6.6) 30 (16.5) 11 (12.1) 5 (5.9) 11 (9.6) 7 (6.6) 
influenza virus 3 (4.0) 29 (15.9) 2 (2.2) 0 (0.0) 6 (5.2) 0 (0.0) 
parainfluenza virus 12 (15.8) 8 (4.4) 9 (9.9) 2 (2.4) 1 (0.9) 3 (2.8) 
adenovirus 7 (9.2) 15 (8.2) 4 (4.4) 7 (8.2) 8 (7.0) 7 (6.6) 
coronavirus 3 (4.0) 12 (6.6) 7 (7.7) 9 (10.6) 14 (12.2) 4 (3.8) 
metapneumovirus 0 (0.0) 7 (3.9) 7 (7.7) 0 (0.0) 3 (2.6) 0 (0.0) 
enterovirus 1 (1.3) 3 (1.7) 8 (8.8) 3 (3.5) 3 (2.6) 4 (3.8) 
parechovirus 6 (6.6) 2 (1.1) 0 (0.0) 1 (1.2) 2 (1.7) 0 (0.0) 
Supplementary table 1: detection of pathogens by season for cases and controls 
RSV: respiratory syncytial virus 
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